BreatheMOR-HF looked at whether prescribing slow release daily morphine tablets to individuals with heart failure helped with breathlessness. We were unable to answer the primary research question due to not reaching the required sample size. But we provided novel placebo-controlled medium-term benefit and safety data useful for clinical practice and future trial design.
Some people with chronic heart failure experience breathlessness despite receiving medication. Persistent breathlessness is associated with poorer physical and mental quality of life, increased unplanned hospital attendance and higher mortality. In people with chronic breathlessness due to chronic obstructive pulmonary disease, regular, low dose, modified release morphine has been shown to be safe and effective in the short term. However, the evidence is less clear for those with chronic heart failure, although preliminary data suggests that these patients may benefit from morphine given for three months.
The trial was the first to provide placebo-controlled data for medium-duration, modified release, steady state, low dose, oral morphine for people with chronic breathlessness receiving guideline-recommended treatments for heart failure. We randomised 45 patients to receive either 10 milligram capsules of modified release morphine or placebo capsules identical in appearance, taste and smell. Patients were followed up for 12 weeks and data collected included average breathlessness, average pain, quality of life and opioid-relevant symptoms.
Patients from England and Scotland were recruited from hospital/community cardiology or palliative care clinics or hospices. On average patients were 72 years old and 84% were male.
We could not answer our primary objectives as we were unable to recruit sufficient participants. However, we provide novel placebo‐controlled medium‐term benefit and safety data useful for clinical practice and future trial design.
Johnson MJ, Cockayne S, Currow DC, Bell K, Hicks K, Fairhurst C, Gabe R, Torgerson D, Jefferson L, Oxberry S, Ghosh J. Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo‐controlled trial. ESC heart failure. 2019 Dec;6(6):1149-60. doi: 10.1002/ehf2.12498
Privacy Notice: How we use your research data
Miriam Johnson
Wolfson Palliative Care Research Centre, University of Hull
Sarah Cockayne
Kerry Bell
Kate Hicks
Caroline Fairhurst
Rhian Gabe
David Torgerson
York Trials Unit, University of York
David Currow
Wolfson Palliative Care Research Centre, University of Hull
IMPACCT, Faculty of Health, University of Technology Sydney
Laura Jefferson
Victoria Allgar
Department of Health Sciences, University of York
Stephen Oxberry
Calderdale & Huddersfield Foundation Trust
Justin Ghosh
Department of Cardiology, Scarborough Hospital
Karen Hogg
Department of Cardiology, Glasgow Royal Infirmary
Jeremy Murphy
Department of Cardiology, Darlington Memorial Hospital
John Cleland
Robertson Centre for Biostatistics & Clinical Trials, University of Glasgow
Andrew Clark
Hull York Medical School
The research was funded by the British Heart Foundation (grant number CS/13/2/30584). The project was started in June 2014 and completed in August 2017.
The study was prospectively registered on ISRCTN (ISRCTN41349358).